AbbVie Inc (ABBV)vsPennant Group Inc (PNTG)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
PNTG
Pennant Group Inc
$39.20
-0.25%
HEALTHCARE · Cap: $1.33B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 5744% more annual revenue ($64.39B vs $1.10B). ABBV leads profitability with a 9.8% profit margin vs 2.9%. ABBV appears more attractively valued with a PEG of 0.52. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
PNTG
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Intrinsic value data unavailable for PNTG.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 35.8% year-over-year
Earnings expanding 25.0% YoY
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Expensive relative to growth rate
Distress zone — elevated risk
Smaller company, higher risk/reward
2.9% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : PNTG
The strongest argument for PNTG centers on Revenue Growth, EPS Growth. Revenue growth of 35.8% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : PNTG
The primary concerns for PNTG are PEG Ratio, Altman Z-Score, Market Cap. A P/E of 42.2x leaves little room for execution misses. Thin 2.9% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a value stock while PNTG is a hypergrowth play — different risk/reward profiles.
PNTG carries more volatility with a beta of 1.27 — expect wider price swings.
PNTG is growing revenue faster at 35.8% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 59/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Pennant Group Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
The Pennant Group, Inc. provides health care services in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company is headquartered in Eagle, Idaho.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?